Simcyp, which was spun-out of the university’s School of Medicine and Biomedical Sciences in 2001, has developed modelling and simulation software that enables pharmaceutical scientists to analyse how a drug is absorbed, distributed, metabolised and excreted in virtual populations of patients, prior to clinical trials in humans.
By including extensive information on demographics, genetics, environmental factors and disease state, complex ‘real-life’ scenarios can be easily investigated including the likelihood and effects of drug-drug interactions.
The company’s flagship product - the Simcyp Population-based ADME Simulator - is used by the world’s top pharmaceutical companies including Pfizer, Johnson & Johnson and AstraZeneca.
The Simcyp simulator helps such pharmaceutical companies to take advantage of routinely generated data to prioritise promising drug candidates earlier in development.
Simulations can also optimise the design of human trials, minimising unnecessary drug exposure to human volunteers and animals. This has significant cost and time-saving benefits in the development of new medicinal products.
This is the second accolade for the Sheffield-based company, which last year was ranked 15th on a list of the fastest-growing businesses in the UK. The firm has continued to expand and expects turnover to increase by a further 20 per cent this year.
Project to investigate hybrid approach to titanium manufacturing
What is this a hybrid of? Superplastic forming tends to be performed slowly as otherwise the behaviour is the hot creep that typifies hot...